Karma Biotechnologies is dedicated to in vivo engineering of the immune system
Karma is an LA based biotech company dedicated to solving the cost, scaling and duration issues associated with ex vivo gene and cell therapies.
- Karma spent five years developing its proprietary, IP protected tech as the basis of our own pipeline of in vivo immunotherapies, with a focus on neuroinflammatory and autoimmune indications.
- Karma’s unique LNP-based technology can convert immune cells in vivo into biofactories that make and secrete therapeutic or immune-system effecting proteins at the site of disease.
- Karma anticipates manufacturing GMP-grade product within 12 months and carrying out first-in-human clinical trials by 2025.
SNIPR: KARMA’S PROPRIETARY LIPID NANOPARTICLE PLATFORM
SNIPR stands for Sub-Nanoparticle Intracellular Payload Release
SAFE
Low toxicity in vitro and in vivo
FLEXIBLE
Can deliver multiple payloads at once
STABLE
Unique process keeps SNIPR stable for weeks at 4oC
SCALABLE
Proprietary robotic manufacturing process
SNIPR PAYLOADS
Their unique 3D structure allows loading of different payloads in controlled ratios
BIOLOGIC DRUGS ENGINEERED IN VIVO
BETTER TISSUE TARGETING
LOWER ANTI-DRUG IMMUNITY
FASTER & CHEAPER TO MAKE
Karma’s unique approach to biotherapeutics enables better outcomes for vast patient populations
NEURO
CANCER
IMMUNITY
KARMA HAS ALREADY ENGINEERED IMMUNE CELLS IN VIVO
We engineer immune cells in vivo to produce bioavailable proteins
Robust DNA & RNA delivery to immune cells
Edits genes in human immune cells
Targeted to immune cells in vivo
Engineers cells to secrete therapeutic or immune-relevant proteins
Secreted therapeutic proteins act in local tissues or on local cells
OUR TEAM
Karma is primed for success with a great mix of geeks and company builders
Andrew Gray, PhD
CO-FOUNDER & CEO
- PhD in Immune tolerance induced by cancer
- IndieBio alum
- Directs Karma’s synthetic bio strategy
Alan Johnson, MBA, BS
CO-FOUNDER & COO
- Synthetic chemist with 20+ years experience
- Iterates and validates Karma’s novel LNPs
Don Johnson, PhD
CO-FOUNDER
- PhD in Biomedical Materials Science
- NIH and IndieBio alum
- Guides Karma’s LNP design strategy
Joe Turner
CFO & CBO
- Previously Managing Director at Blackstone/PJT
- MS Finance NYU
- Leads Karma’s finance and business strategy, including commercial partnerships
Luciana C. Veiras, PhD
SENIOR SCIENTIST
- Immunophysiologist
Xazmin Custer, PhD
MOLECULAR BIOLOGIST
- Metabolism & cell signaling expert
Mariana Uchoa, PhD
NEUROIMMUNOLOGIST
- XavineTM research & development lead
ADVISORY BOARD
Karma has exceptional VC backers and is actively building an expert SAB
Todd Peterson, PhD
FOUNDER, GENAPEX BIO
Former CSO of Allen Institute & former CTO of Viridos
James Treanor, PhD
BoD MEMBER, ADRX
Founding CEO, ADRx & 18 years at AMGEN
W. Martin Kast, PhD
PROFESSOR & DEAN, USC
Immune regulation guru
Paul Feldstein, PhD
CSO, CIRCULARIS
Cell-specific expression expert
Andy Alexander, PhD DVM, DABT, MBA
PRESIDENT, SBA INC.
FDA whisperer
Mike Siani-Rose
SIANI-ROSE CONSULTING
Project management and biopharma manufacturing pro
INVESTORS
CAREERS
Interested in joining the team at Karma?
Here are our current openings:
- Scientist, Nanotechnology / Materials Science
Torrance, CA - Scientist, Immunology
Torrance, CA - Scientist, Molecular Biology
Torrance, CA - Research Associate, Immunology
Torrance, CA - Research Associate, Molecular Biology
Torrance, CA
CONTACT US
Karma Biotechnologies
LOCATION
370 Amapola Avenue, Suite 101
Torrance, CA 90501
FOLLOW US ON SOCIAL MEDIA
LinkedIn
www.linkedin.com/company/karma-biotechnologies
Twitter
www.twitter.com/karmabiotech
Instagram
www.instagram.com/karmabiotech